Novo drops Hims & Hers partnership

Novo Nordisk’s split with Hims & Hers was not a retreat from telehealth. It was a fight over which channels the drugmaker would trust to distribute Wegovy and related obesity medicines. In June 2025, Novo said it had terminated its collaboration with Hims & Hers over what it described as illegal mass compounding and deceptive marketing tied to semaglutide products. (pharmacytimes.com) March 9, 2026, briefly looked like a reset. Hims & Hers announced a new collaboration with Novo and said Ozempic and Wegovy injections, along with Wegovy pills, would come to its platform later that month. (investors.hims.com) The company also said it would no longer advertise compounded GLP-1 offerings and would help existing patients transition to FDA-approved medicines when clinicians deemed that appropriate. (corporate.ww.com) That arrangement did not hold. Trade and healthcare publications later reported that Novo again cut ties with Hims & Hers while expanding access through Weight Watchers, a partner already positioned inside Novo’s NovoCare distribution framework. ### Why did Novo break with Hims & Hers? (pharmacytimes.com) June 2025 is the key date because that is when Novo publicly tied the breakup to Hims & Hers’ semaglutide business. Pharmacy Times reported that Novo said the decision stemmed from concerns about “illegal mass compounding and deceptive marketing.” CNBC separately reported in February 2026 that Novo had threatened legal action over what it called “illegal mass compounding” tied to a copycat Wegovy pill. February 7, 2026, added another flashpoint. (investors.hims.com) Hims & Hers said it would stop offering its copycat Wegovy pill after threats of legal action from Novo and the U.S. Food and Drug Administration, according to CNBC. The FDA, CNBC reported, said it planned legal action that could include restricting access to ingredients and referring the company to the Justice Department. (pharmacytimes.com) ### What exactly is the compounding issue? The FDA has warned that some compounded semaglutide products can create dosing risks and may use ingredients different from those in approved drugs. The agency has said it has received reports of adverse events, including some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide. (pharmacytimes.com) The FDA has also said it is aware of counterfeit Ozempic in the U.S. supply chain and has warned consumers about unapproved GLP-1 drugs used for weight loss. The agency said counterfeit products may contain the wrong ingredients, too much or too little active ingredient, or none at all. It has also flagged semaglutide sodium and semaglutide acetate as concerns in unapproved products. (cnbc.com) ### Why did Novo move toward Weight Watchers instead? June 26, 2025, is when Weight Watchers disclosed a Wegovy partnership with Novo that used CenterWell Pharmacy to fulfill and deliver the drug, according to Fierce Healthcare. Novo U.S. operations chief Dave Moore said then that the company would keep building agreements with companies that “share our values” and help improve access to FDA-approved medicines. (fda.gov) January 5, 2026, showed how that relationship broadened. Weight Watchers said its affiliated clinic was a NovoCare Recognized Care Provider and that it would offer Novo’s oral Wegovy through its Med+ platform. The company said its program combines board-certified clinicians, behavioral support, coaching and digital tools alongside medication access. (fda.gov) ### What does this mean for patients using GLP-1 telehealth services? March 9, 2026, remains important because Hims & Hers had told customers it would shift away from advertising compounded GLP-1s and toward approved medicines. But Novo’s subsequent exit shows the drugmaker was not willing to leave channel control to a partner it believed had crossed its compliance lines. (fiercehealthcare.com) NovoCare’s current patient materials point consumers to in-person and telehealth doctors for weight-loss treatment, while Weight Watchers continues to market Wegovy access through Med+. For patients, the next concrete step is not a policy debate but where prescriptions are written, dispensed and supported — through channels Novo continues to recognize. (novocare.com) (investors.hims.com) (corporate.ww.com)